NewsResearch
CheckMate 577: What the Esophageal Cancer Trial Found
CheckMate 577 built a treatment for a gap in the pathway: people whose oesophageal cancer was still present in the specimen after chemoradiation and surgery. A year of nivolumab roughly doubled the time before recurrence.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A gap in the treatment path, and a trial built for it
The standard route for stage II or III oesophageal cancer is chemotherapy with radiation, then surgery. When the surgeon removes the oesophagus, a pathologist examines what came out.
Sometimes there is no cancer left in the specimen. Those people do well. Sometimes cancer is still there, which means the chemoradiation did not clear it. Those people are at high risk of recurrence, and before this trial there was nothing proven to offer them.
CheckMate 577 enrolled only the second group.
Who qualified: the residual-disease rule
| Field | Detail |
|---|---|
| Trial | CheckMate 577 |
| Identifier | NCT02743494 |
| Phase | Phase 3 |
| Design | Randomised 2:1, double-blind, placebo-controlled |
| Cancer type | Stage II or III oesophageal or gastro-oesophageal junction cancer, completely removed after chemoradiation, with cancer still in the specimen |
| Comparator | Nivolumab against matching placebo, for up to one year |
| Primary endpoint | Disease-free survival |
794 adults took part: 532 assigned nivolumab and 262 placebo. Surgery had to have been complete, with no cancer at the cut edges — what surgeons call an R0 resection.
The infusions ran every two weeks for the first 16 weeks, then every four weeks, with the amount worked out by the treating team each time. Treatment stopped at one year, whatever happened.
Disease-free survival roughly doubled
Median disease-free survival — the time before the cancer came back or the person died — was 22.4 months with nivolumab (95% CI 16.6 to 34.0) and 11.0 months with placebo (95% CI 8.3 to 14.3).
The hazard ratio was 0.69 (96.4% CI 0.56 to 0.86, p<0.001). The benefit showed up across the pre-specified subgroups the investigators looked at. Median follow-up was 24.4 months.
What was not measured
Overall survival is not in this report. The trial showed that recurrence was delayed. It did not show, at this point, that people live longer.
Those are different claims, and the difference matters here more than usual. Delaying a recurrence by eleven months is worth something on its own. Whether it changes how long someone lives is a question this analysis leaves open.
Side effects over a year of treatment
Severe side effects — grade 3 or 4 — that investigators put down to the study drug occurred in 71 of 532 people on nivolumab (13%) and 15 of 260 on placebo (6%).
9% of the nivolumab group stopped treatment because of side effects, against 3% on placebo. This is a year of infusions given to people who have just been through chemoradiation and major surgery, so tolerability is not a minor consideration.
What this does not mean
- It does not mean people live longer. That was not reported here.
- It does not apply if there was no cancer left in the specimen. Those people were not eligible.
- It does not apply after chemotherapy alone before surgery. Everyone here had chemoradiation.
- It does not settle how long treatment should run. One year was the cap the protocol set, not a duration the trial tested against alternatives.
Questions after oesophageal surgery
- Did the pathology report show cancer still present in what was removed?
- Was my resection complete at the margins?
- What would a year of infusions involve while I am still recovering from surgery?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
- NEJM: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) (primary)
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Esophageal cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.